₹ 4,970/Bottle
Product Name Temzol Generic Name Temozolomide Manufacturer Getwell Type Capsules Strength 100 mgDOSAGE AND ADMINISTRATION Dosage of Temozolomide must be adjusted according to nadir neutrophil and platelet counts in the previous cycle and the neutrophil and platelet counts at the time of initiating the next cycle. Patients with Newly Diagnosed High Grade Glioma Temozolomide is administered at 75 2 mg/m daily for 42 days concomitant with focal radiotherapy (60 Gy administered in 30 fractions) followed by maintenance Temozolomide for 6 cycles. Focal RT includes the tumor bed or resection site with a 2- to 3-cm margin. No dose reductions are recommended during the concomitant phase; however, dose interruptions or discontinuation may occur based on toxicity. Temozolomide dose should be continued throughout the 42-day concomitant period up to 49 days if all of the following conditions are met absolute neutrophil count greater than or equal to 9 9 1.5 x 10 /L, platelet count greater than or equal to 100 x 10 /L, common toxicity criteria (CTC) nonhematological toxicity less than or equal to Grade 1 (except for alopecia, nausea, and vomiting). During treatment a complete blood count should be obtained weekly. Temozolomide dosing should be interrupted or discontinued during concomitant phase according to the hematological and nonhematological toxicity criteria as noted in Table 1. Pneumocystis pneumonia (PCP) prophylaxis is required during the concomitant administration of Temozolomide and radiotherapy, and should be continued in patients who develop lymphocytopenia until recovery from lymphocytopenia (CTC Grade less than or equal to 1) TABLE 1 Temozolomide Dosing Interruption or Discontinuation During ConcomitantCONTRAINDICATION Temozolomide is contraindicated in patients who have a history of hypersensitivity reaction (such as urticaria, allergic reaction including anaphylaxis, toxic epidermal necrolysis, and Stevens-Johnson syndrome) to any of its components. Temozolomide is also contraindicated in patients who have a history of hypersensitivity to dacarbazine (DTIC), since both drugs are metabolized to 5-(3-methyltriazen-1-yl)-imidazole-4- carboxamide (MTIC). It is also contraindicated in pregnancy and lactationADVERSE EFFECTS The most frequently occurring side effects are nausea, vomiting, headache and fatigue. The adverse events are usually NCI common Toxicity Criteria (CTC) Grade 1 or 2 (mild to moderate in severity) and are self limiting , with nausea and vomiting, readily controlled with an antiemetics. Hematologic toxicities Myelosuppression (thrombocytopenia and neutropenia) usually occurs within the first few cycles of therapy and is the dose-limiting adverse event. The incidence of thrombocytopenia and neutropenia was approximately three times higher in females. Pediatric patients appeared to tolerate higher plasma concentrations of temozolomide before reaching dose limiting toxicity.